U.S. Media Stock News

In late March 2026, Morgan Stanley downgraded AvalonBay Communities to Equalweight following Q4 results, pointing to guidance that implies almost flat core funds from operations per share this year. While Morgan Stanley cut near-term expectations more than peers, it still highlights AvalonBay’s potential for stronger earnings growth further out. With Morgan Stanley flagging a flat near-term earnings outlook, we’ll now examine how this shift affects AvalonBay’s broader investment narrative...

Why BBB Foods’ latest SEC filing matters for shareholders BBB Foods (NYSE:TBBB) recently filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, giving investors a detailed, audited look at the Mexican hard discount grocer’s operations and financial position. This filing follows the company’s recent stock exchange listing and rapid store expansion in Mexico. It offers a single source for updated financial statements, risk disclosures, and governance information...

Why Ingevity’s new credit agreement matters for shareholders Ingevity (NGVT) recently amended and restated its main credit agreement, extending the maturity of its revolving credit facility by five years, trimming total commitments to US$750 million, and updating interest terms. At the same time, the company repaid US$512.1 million of outstanding revolving loans under the prior facility. This gives investors a clearer view of its current leverage, liquidity access, and banking...

On March 11, 2026, Perrigo Company plc outlined at the UBS Global Consumer and Retail Conference its plans to focus on core businesses, deepen retailer partnerships and cut about 7% of its global workforce to streamline operations amid a soft market backdrop. An interesting angle for investors is how Perrigo aims to balance these cost reductions with continued investment in innovation, geographic expansion and a maintained dividend policy while signaling 2027 as a key year for accelerating...

Why Regency Centers Is Back in Focus Regency Centers (REG) is drawing attention after recent commentary highlighted its push to expand development with top tenants and build out data analytics and AI tools to support efficiency and decision-making. See our latest analysis for Regency Centers. Those development and AI plans come as the share price sits at $76.98, with a 13.27% year to date share price return and a 62.08% five year total shareholder return. This suggests momentum has recently...

Papa John's International (PZZA) has moved further beyond its core pizza offering, rolling out Oven Toated Sandwiches and pairing the launch with a short window Pizza Miles rewards promo aimed at carryout customers. See our latest analysis for Papa John's International. The recent product launch and governance proposals come as the 1 month share price return of 9.38% and 1 week gain of 7.20% contrast with a 1 year total shareholder return decline of 10.68%. This may signal short term momentum...

Why Shoals Technologies Group (SHLS) Is Back on Investors’ Radar Interest in Shoals Technologies Group (SHLS) has picked up as options activity signals heightened expectations for price swings, just as the company showcases its battery energy storage solutions in a Barclays hosted webinar. See our latest analysis for Shoals Technologies Group. At a share price of US$6.82, Shoals has seen a 15.4% 1 month share price return. Its year to date share price return of 24.97% and 3 year total...

Recent analyst activity around Equity LifeStyle Properties (ELS) has picked up, with Mizuho initiating coverage and BofA Securities upgrading the stock, while BMO Capital maintains a supportive stance that may be shaping current investor sentiment. See our latest analysis for Equity LifeStyle Properties. The share price at US$63.99 has a 1-day share price return of 1.15% and a 90-day share price return of 7.02%. However, the 1-year total shareholder return of a 2.68% decline suggests recent...

PTC Therapeutics recently appointed longtime Morgan Stanley healthcare banker Jessica Chutter to its Board of Directors as a Class I director, effective March 24, 2026, with standard outside-director compensation including a US$50,000 annual retainer and expense reimbursement. Her four decades of experience advising biotechnology and pharmaceutical companies on mergers, capital raising, and valuation bring capital-markets depth that could influence how PTC Therapeutics approaches future...

Why FedEx SameDay Local matters for FDX shares FedEx (FDX) just rolled out FedEx SameDay Local, a two hour and end of day delivery service built with OneRail, aiming to capture rising demand for faster, more predictable last mile shipping. See our latest analysis for FedEx. FedEx shares recently showed strong momentum, with a 7 day share price return of 3.46% and a 90 day share price return of 23.37%. The 1 year total shareholder return of 71.25% points to solid longer term gains, even after...

AMETEK (AME) is back on investors’ radar after a fresh Outperform rating highlighted its diversified business mix and shorter-cycle operations, as well as price strength alongside broader electronic equipment and semiconductor peers. See our latest analysis for AMETEK. Even after a recent pullback, with a 30 day share price return of 7.21% and a 1 day move slightly lower, AMETEK’s 1 year total shareholder return of 36.05% and 3 year total shareholder return of 64.57% point to momentum that...

Viridian Therapeutics (VRDN) just reported positive topline Phase 3 REVEAL-1 data for elegrobart in active thyroid eye disease, with both dosing schedules meeting key proptosis and diplopia endpoints versus placebo. See our latest analysis for Viridian Therapeutics. Even with the encouraging REVEAL-1 topline readout, Viridian’s recent 7 day share price return of 33.19% and 30 day share price return of 35.74% show momentum has faded. However, the 1 year total shareholder return of 48.93% still...

IDEX (IEX) has drawn attention after recent trading left the shares roughly 9% lower over the past month, even as the past 3 months show a gain of about 6%. See our latest analysis for IDEX. That 8.9% 1 month share price return decline comes after a 6.4% 3 month share price gain. The 1 year total shareholder return of 14.7% contrasts with weaker 3 and 5 year total shareholder returns, suggesting momentum has been improving more recently than over the longer term. If you are weighing what else...

In late March 2026, Yum China filed preliminary proxy materials for its 2026 annual meeting, outlining planned shareholder votes on board elections, auditor ratification, executive pay, and authorizations for share issuance and buybacks. A fresh analyst update from Macquarie, alongside these proxy proposals, is refocusing attention on how Yum China may balance growth investment with flexible capital returns. We will now examine how Yum China’s proposed share issuance and buyback...

Universal Display Corporation recently presented at the International Conference on Display Technology 2026 in Chongqing, China, where senior leaders showcased advances in its OLED emissive layer technology and high-efficiency PHOLED materials. The company’s active technical presence at ICDT 2026, alongside ongoing work on blue emitters, underlines its efforts to keep its OLED platform central to future display innovation. We’ll now examine how Roth Capital’s reaffirmed positive outlook,...

Alignment Healthcare recently reported quarterly results showing revenue up 44.4% year on year and earnings per share above analyst estimates, while also updating guidance that implied weaker-than-expected revenue for the next quarter. Alongside this mixed earnings picture, the company highlighted ongoing expansion of its Medicare Advantage offerings and national footprint, underscoring a continued push to scale its coordinated, technology-enabled care model. Next, we’ll explore how this...

Summit Therapeutics Inc. recently presented data for its investigational bispecific antibody ivonescimab at the 2026 European Lung Cancer Congress in Copenhagen, highlighting progress in multiple Phase III trials across non-small cell lung cancer and colorectal cancer. The company now has 15 announced, ongoing, or completed Phase III studies for ivonescimab, including four Summit-sponsored global trials and ten China-based trials run by partner Akeso Inc., underscoring how extensively this...

BorgWarner (BWA) stock has drawn fresh attention after recent share price moves, with a 1-day return of around a 3% decline and a 7-day return of about a 4% decline prompting closer scrutiny from investors. See our latest analysis for BorgWarner. While the recent 1-day and 7-day share price returns are negative, BorgWarner’s 90-day share price return of 13.27% and 1-year total shareholder return of 96.94% suggest earlier momentum that contrasts with the latest pullback. If you are weighing...

In early April 2026, Booking Holdings completed its first-ever 25-for-1 forward stock split following a quarter of revenue and adjusted EPS growth alongside a higher dividend. By pairing the stock split with stronger financial results and guidance, the company is signalling confidence in its ability to keep generating cash and broadening its investor base. Next, we'll examine how this unprecedented 25-for-1 stock split and earnings momentum may reshape Booking Holdings' investment...

Ionis Pharmaceuticals (IONS) is back in focus after the FDA accepted its New Drug Application for zilganersen and granted Priority Review, a key regulatory step for its Alexander disease program. See our latest analysis for Ionis Pharmaceuticals. The FDA news comes after a mixed recent run for the stock. A 1-year total shareholder return of 162.24% contrasts with weaker 30-day and year-to-date share price returns, suggesting strong longer term momentum while shorter term enthusiasm has...

Conference messages and analyst attention put Waters back in focus Waters (WAT) has moved back onto investors' radar after its recent health care conference comments on growth priorities and BD Diagnostic Solutions integration, alongside a renewed supportive view from a major Wall Street bank. See our latest analysis for Waters. After a weak patch that left the 90 day share price return at a 20.35% decline and the 1 year total shareholder return at an 11.85% loss, recent gains around the TD...

Moody’s recently issued its first credit rating on Bitcoin-backed bonds, assigning a Ba2 rating to up to US$100 million of revenue bonds issued through the New Hampshire Business Finance Authority and collateralized by Bitcoin held in custody. This move shows how Moody’s is beginning to apply its traditional credit framework to crypto-backed securities, signaling a cautious but meaningful step toward integrating digital assets into mainstream risk assessment. We’ll now examine how Moody’s...

Why Greenbrier Companies (GBX) May Be On Your Radar Greenbrier Companies (GBX) has drawn attention after recent share performance data showed mixed returns, with the stock up over the past year but showing a decline over the past month. This pattern has prompted fresh interest in its rail focused business model. See our latest analysis for Greenbrier Companies. Recent moves have been mixed, with a 30 day share price return of a 6.9% decline, a 90 day share price return of 11.6%, and a three...

Adeia Inc. recently reiterated its full-year 2026 guidance, projecting GAAP revenue of US$395.0 million–US$435.0 million and net income of US$57.2 million–US$80.4 million, while its subsidiaries filed a patent infringement lawsuit against Dish Network over five media and pay-TV patents. The combination of reaffirmed financial targets and active enforcement of its media intellectual property underscores how central licensing and litigation are to Adeia’s business model. We’ll now examine how...